Medley, Inc. (JP:4480)
:4480
Want to see JP:4480 full AI Analyst Report?
Top Page
Medley
(4480)
Select Model
Select Model
Rating:51Neutral
Price Target:
¥2,324.00
▼(-0.68% Downside)
Action:Reiterated
Date:02/18/26
The score is primarily constrained by weak technicals (price below all major moving averages and bearish momentum) and elevated valuation (high P/E with no dividend yield data). Financial performance is mixed: strong revenue growth and positive cash flow are outweighed by sharp 2025 margin compression and increased leverage.
Positive Factors
Revenue Growth
Sustained multi-year revenue expansion indicates strong market demand and successful commercial execution. A fivefold increase in top line builds scale advantages, supports long-term investment in product and distribution, and creates a larger base to absorb periodic profit shocks over 2–6 months.
Negative Factors
Net Margin Compression
A sharp drop in net margin materially weakens profitability and the firm’s ability to convert revenue into retained earnings. This deterioration suggests rising costs or one-off pressures that impair sustainable earnings power and reduce financial cushioning against future revenue variability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained multi-year revenue expansion indicates strong market demand and successful commercial execution. A fivefold increase in top line builds scale advantages, supports long-term investment in product and distribution, and creates a larger base to absorb periodic profit shocks over 2–6 months.
Read all positive factors
Medley (4480) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥71.00B
Dividend YieldN/A
Average Volume (3M)504.45K
Price to Earnings (P/E)―
Beta (1Y)0.33
Revenue Growth23.30%
EPS Growth-56.05%
CountryJP
Employees1,487
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding32,738,600
10 Day Avg. Volume497,800
30 Day Avg. Volume504,450
Financial Highlights & Ratios
PEG Ratio-1.19
Price to Book (P/B)5.08
Price to Sales (P/S)2.04
P/FCF Ratio22.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Medley Business Overview & Revenue Model
Company Description
Medley, Inc. operates platforms for recruitment and medical businesses in Japan. It operates through three segments: HR Platform Business, Medical Platform Business, and New Services. The company manages JobMedley, a human resource recruitment sys...
How the Company Makes Money
null...
Medley Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
52
Neutral
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.06B | 36.79B | 29.30B | 20.53B | 14.19B | 10.86B |
| Gross Profit | 20.74B | 23.19B | 18.92B | 13.59B | 9.72B | 6.99B |
| EBITDA | 5.03B | 4.61B | 4.00B | 4.50B | 2.14B | 1.25B |
| Net Income | 1.44B | 975.00M | 2.80B | 2.57B | 1.02B | 563.00M |
Balance Sheet | ||||||
| Total Assets | 47.42B | 41.25B | 45.41B | 25.52B | 22.04B | 20.33B |
| Cash, Cash Equivalents and Short-Term Investments | 13.52B | 8.57B | 19.00B | 15.35B | 14.42B | 14.29B |
| Total Debt | 18.27B | 16.09B | 15.18B | 1.66B | 2.38B | 3.11B |
| Total Liabilities | 29.36B | 26.45B | 25.19B | 7.89B | 6.87B | 6.28B |
| Stockholders Equity | 18.07B | 14.80B | 20.21B | 17.55B | 15.08B | 13.97B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 3.28B | 2.38B | 3.47B | 1.64B | 796.39M |
| Operating Cash Flow | 0.00 | 3.49B | 2.45B | 3.87B | 2.01B | 1.04B |
| Investing Cash Flow | 0.00 | -7.13B | -10.72B | -1.66B | -751.00M | -3.29B |
| Financing Cash Flow | 0.00 | -6.78B | 11.90B | -1.22B | -927.00M | 2.22B |
Medley Technical Analysis
Positive
2340.00
Price Trends
2008.42
Positive
2218.57
Positive
2445.10
Negative
Market Momentum
73.90
Negative
73.45
Negative
92.04
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4480, the sentiment is Positive. The current price of 2340 is above the 20-day moving average (MA) of 2009.90, above the 50-day MA of 2008.42, and below the 200-day MA of 2445.10, indicating a neutral trend. The MACD of 73.90 indicates Negative momentum. The RSI at 73.45 is Negative, neither overbought nor oversold. The STOCH value of 92.04 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4480.
Medley Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ¥920.15B | 36.11 | 12.15% | 1.01% | 23.33% | 21.65% | |
60 Neutral | ¥175.90B | 31.32 | ― | 0.43% | 20.95% | 13.39% | |
54 Neutral | ¥10.17B | 34.60 | ― | 5.30% | 15.59% | -80.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥71.00B | -232.45 | 5.76% | ― | 23.30% | -56.05% | |
44 Neutral | ¥2.41B | -4.65 | ― | ― | 18.86% | 38.80% |
* Healthcare Sector Average
JP:4480
Medley
2,169.00
-1,031.00
-32.22%
JP:2413
M3
1,355.00
-569.80
-29.60%
JP:4438
Welby Inc.
286.00
-63.00
-18.05%
JP:4483
JMDC Inc.
2,688.00
-438.79
-14.03%
JP:9341
GENOVA Inc.
570.00
-123.62
-17.82%
Medley Corporate Events
Medley Corrects SG&A Breakdown in FY2026 Q1 Results Materials
May 14, 2026
Medley, Inc. has announced corrections to its presentation materials for fiscal 2026 first-quarter financial results, specifically revising the breakdown of selling, general and administrative expenses. The adjustment affects only the internal cla...
Medley Posts Strong Revenue Growth but Quarterly Loss, Reaffirms Robust 2026 Outlook
May 13, 2026
Medley reported consolidated net sales of ¥10.19 billion for the quarter ended March 31, 2026, up 25.2% year on year, with EBITDA rising 48.1% to ¥631 million but a slight operating loss of ¥67 million and a net loss attributable to...
Medley to Acquire Recruit Medical Career’s Healthcare Staffing Business
Mar 27, 2026
Medley, Inc. will acquire all shares of RM CAREER Co., Ltd., a newly formed entity that will inherit the physician and pharmacist recruitment support operations of Recruit Medical Career Co., Ltd., turning it into a wholly owned subsidiary for 1.0...
Medley Nears ¥3 Billion Share Buyback Cap With Completion of Latest Repurchase
Mar 3, 2026
Medley has completed a share repurchase program authorized by its board in November 2025, buying back 22,100 common shares for ¥41.6 million via market transactions on the Tokyo Stock Exchange between March 1 and 2, 2026. This transaction for...
Medley Nears Completion of ¥3 Billion Share Buyback Program
Mar 2, 2026
Medley, Inc. reported progress on its ongoing share repurchase program authorized by its board in November 2025, detailing that it bought back 840,100 common shares on the Tokyo Stock Exchange between February 1 and February 28, 2026, for a total ...
Medley Moves to Expand Business Scope With Articles of Incorporation Revision
Feb 24, 2026
Medley, Inc. plans to broaden its corporate purposes through amendments to its Articles of Incorporation to support future business expansion and development. The revisions, to be submitted for approval at the March 27, 2026 annual shareholders me...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.